Summit Global Investments raised its stake in Johnson & Johnson (NYSE:JNJ) by 16.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 57,784 shares of the company’s stock after buying an additional 8,317 shares during the period. Johnson & Johnson comprises 2.3% of Summit Global Investments’ portfolio, making the stock its 3rd largest position. Summit Global Investments’ holdings in Johnson & Johnson were worth $7,197,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of JNJ. State Street Corp increased its position in shares of Johnson & Johnson by 4.3% in the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after buying an additional 6,656,371 shares during the last quarter. Norges Bank purchased a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $3,220,322,000. Schwab Charles Investment Management Inc. increased its position in shares of Johnson & Johnson by 1.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 11,150,339 shares of the company’s stock worth $1,388,775,000 after buying an additional 201,703 shares during the last quarter. Fisher Asset Management LLC increased its position in shares of Johnson & Johnson by 1.2% in the first quarter. Fisher Asset Management LLC now owns 11,093,898 shares of the company’s stock worth $1,381,745,000 after buying an additional 136,764 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of Johnson & Johnson by 0.5% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,948,942 shares of the company’s stock worth $990,041,000 after buying an additional 42,144 shares during the last quarter. Institutional investors and hedge funds own 66.10% of the company’s stock.

Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.05% during midday trading on Monday, hitting $133.17. 695,421 shares of the stock were exchanged. The company has a market cap of $357.43 billion, a PE ratio of 22.53 and a beta of 0.78. The firm has a 50-day moving average price of $133.09 and a 200-day moving average price of $126.30. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The business had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. During the same period in the previous year, the business posted $1.74 EPS. The company’s quarterly revenue was up 1.9% on a year-over-year basis. On average, equities analysts predict that Johnson & Johnson will post $7.18 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.52%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 56.76%.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.watchlistnews.com/johnson-johnson-jnj-shares-bought-by-summit-global-investments/1487013.html.

JNJ has been the subject of a number of analyst reports. BidaskClub upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 17th. Jefferies Group LLC reiterated a “hold” rating and set a $135.00 target price (down previously from $140.00) on shares of Johnson & Johnson in a research note on Sunday, May 14th. Royal Bank Of Canada reiterated a “buy” rating and set a $128.00 target price on shares of Johnson & Johnson in a research note on Thursday, June 15th. Atlantic Securities downgraded shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 target price for the company. in a research note on Friday, July 21st. Finally, Barclays PLC reiterated an “equal weight” rating and set a $130.00 target price (up previously from $125.00) on shares of Johnson & Johnson in a research note on Monday, April 17th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company’s stock. Johnson & Johnson currently has an average rating of “Hold” and a consensus price target of $133.72.

In other news, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now directly owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now directly owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. Insiders own 0.19% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.